COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy
- 4 August 2020
- journal article
- editorial
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 173 (3), 237-238
- https://doi.org/10.7326/m20-3047
Abstract
Mackey and colleagues reported a systematic review that found high-certainty evidence that angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with greater...This publication has 7 references indexed in Scilit:
- Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsAnnals of Internal Medicine, 2020
- Keeping Up With Emerging Evidence in (Almost) Real TimeAnnals of Internal Medicine, 2020
- Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19The New England Journal of Medicine, 2020
- Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?Journal of Hypertension, 2020
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19The New England Journal of Medicine, 2020
- Renin-angiotensin-aldosterone system and COVID-19 infectionAnnales d'Endocrinologie, 2020
- Clinical consequences of angiotensin-converting enzyme inhibitor withdrawl in chronic heart failure: A double-blind, placebo-controlled study of quinaprilJournal of the American College of Cardiology, 1993